Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
Sponsor: Genascence Corporation
Summary
The goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (AAV) gene therapy (GNSC-001) is safe and tolerated compared to placebo in participants with painful osteoarthritis (OA) of the knee.
Official title: A Phase 1b, Randomized, Double-Blinded, Placebo-Controlled Dose Ranging Study to Evaluate Safety, Tolerability and Pharmacodynamics of a Single Intra-articular Injection of GNSC-001 Gene Therapy in Subjects With Osteoarthritis of the Knee
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
67
Start Date
2023-06-12
Completion Date
2029-05
Last Updated
2025-08-01
Healthy Volunteers
No
Interventions
GNSC-001
intra-articular injection
transient immune-modulation
oral
transient immune-modulation
intra-articular injection
Placebo
intra-articular injection
Locations (9)
Alliance for Medical Research Mobile
Mobile, Alabama, United States
Biosolutions Clinical Research Center
La Mesa, California, United States
UC San Diego
San Diego, California, United States
Well Pharma Medical Research
Miami, Florida, United States
South Florida Research
Miami Springs, Florida, United States
Premier Medical Associates
The Villages, Florida, United States
Alliance for Multispecialty Research Kansas City
Kansas City, Missouri, United States
West Clinical Research
Morehead City, North Carolina, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States